William Bachinsky

Mar 9, 2024 | jamanetwork.com | Robert W. Yeh |Richard A Shlofmitz |Jeffrey W. Moses |William Bachinsky

Key PointsQuestion  Is treatment with a coronary paclitaxel-coated balloon superior to an uncoated balloon for 1-year target lesion failure in patients undergoing percutaneous coronary intervention for in-stent restenosis? Findings  In a multicenter randomized trial of 600 patients designed to support US regulatory approval, target lesion failure was significantly lower in the paclitaxel-coated balloon group (17.9%) compared with the uncoated balloon group (28.6%) (P = .003).